Asterias Biotherapeutics’ CEO Michael Mulroy to Participate on Regenerative Medicine Therapies Panel at the B. Riley FBR Healthcare Conference

FREMONT, Calif., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today announced that Michael Mulroy, President and Chief Executive Officer, will participate in a panel discussion at the B. Riley FBR Healthcare Conference at 8:20am ET/5:20 am PT on Tuesday, September 4, 2018 in New York. 

The discussion will be moderated by George Zavoico, Senior Research Analyst, SVP Equity Research, B. Riley FBR and the other panelists will include senior executives from other regenerative medicine therapies companies.

Mr. Mulroy will be meeting with investors throughout the conference and one-on-one meetings may be scheduled through the B. Riley 1x1 desk or by contacting Michael Polyviou, at 732-933-2754 or .

About Asterias Biotherapeutics

Asterias Biotherapeutics, Inc. is a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer. Asterias is presently focused on advancing three clinical-stage programs which have the potential to address areas of very high unmet medical need in the fields of neurology and oncology. AST-OPC1 (oligodendrocyte progenitor cells) is currently in a Phase 1/2a dose escalation clinical trial in spinal cord injury. AST-VAC2 (antigen-presenting allogeneic dendritic cells) is an allogeneic cancer immunotherapy. The company's research partner, Cancer Research UK, has commenced a first-in-human clinical trial of AST-VAC2 in non-small cell lung cancer. AST-VAC1 (antigen-presenting autologous dendritic cells) is an autologous cancer immunotherapy with promising efficacy and safety data from an earlier Phase 2 study in Acute Myeloid Leukemia (AML).  Asterias is also sponsoring pre-clinical work in two conditions with a demyelinating component: Multiple Sclerosis and White Matter Stroke, and is evaluating other cancer indications where its immunotherapy platform could provide therapeutic benefit. Additional information about Asterias can be found at       

Contacts:

Investor Relations

(510) 456-3892



or

EVC Group, Inc.

Michael Polyviou/Todd Kehrli

(732) 933-2754

;